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CFTR mutation, which causes cystic ﬁbrosis (CF), has been identiﬁed as causing
glutathione system dysfunction and systemic deﬁciency of reduced glutathione
(GSH). Such dysfunction and deﬁciency regarding GSH may contribute to the
pathophysiology of CF.
11 patients (age range 5−27 years) with CF, who were using a regimen of reduced
glutathione (GSH), including oral and inhaled buffered glutathione, were followed in
an uncontrolled observational study. Dosage in all cases was 60mg/kg/day divided
into 4 doses, and the term examined was the initial 6 months of GSH use (60 days
of incrementally adjusted dose plus 4 months of use at full dosage). Pre- and post-
measurements of FEV1 percent predicted, BMI percentile, and weight percentile
were noted, in addition to bacterial status and pulmonary exacerbations.
Signiﬁcant improvement in the following clinical parameters was observed: aver-
age improvement in FEV1 percent predicted (N= 10) was 5.8 percentage points
(p< 0.0001), average weight percentile (N = 11) increased 13.7 points (p< 0.0001),
BMI percentile (N = 11) improved on average 1.22 points (p< 0.0001). All patients
improved in each of these three parameters. Positive sputum cultures of bacteria in
11 patients declined from 13 to 5 (p< 0.03) with sputum cultures of Pseudomonas
aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including
two of three patients chronically infected with PA as determined by antibody status.
Use of a daily GSH regimen appears to be associated in CF patients with signiﬁcant
improvement in lung function and weight, and a signiﬁcant decline in bacteria
cultured in this study. These ﬁndings bear further clinical investigation in larger
controlled studies.
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Aims: Azithromycin (AZM) is beneﬁcial in patients with Cystic Fibrosis (CF) who
are chronically colonised with Pseudomonas aeruginosa (PA). We investigated the
role of AZM in improving quality of life and lung function of CF patients not
infected with PA.
Methods: A randomised double-blind crossover study was performed in the Pae-
diatric and Adult CF centres in Northern Ireland.
CF patients, aged 6−20 years, were included if they were PA free for 12months
and able to perform spirometry. Patients were excluded if they had B. cepacia
complex, S. maltophilia, MRSA, or mycobacterium; if they had a known allergy to
macrolides, abnormal liver function tests or a family history of deafness.
Subjects were randomised to receive either 4 months AZM followed by 4 months
Placebo or vice versa, with a 2 month washout period between each treatment.
Dose of AZM; 250mg (weight 40 kg) or 500mg (40 kg), on 3days/week.
Clinical assessment and spirometry was carried out every 2 months, a quality of
life questionnaire was completed at the start and end of each treatment period.
Results: 22 started the study (11 male) and 17 patients completed both sequences.
There was no ‘carryover’ effect. We found a trend for the CFQ ‘vitality’ score to
improve with AZM treatment (beta coeff. 3.8, 95%CI: −0.2 to 8.0, p = 0.06). There
were no improvements observed in lung function (FEV1 p = 0.7, FVC p= 0.3) or
CFQ respiratory symptoms (p = 0.3).
Conclusion: This cross-over study of non-PA CF patients found AZM did not
improve lung function, but did observe a trend for improvement in vitality scores
which for some patients were large. A larger multi-centred study is required to
explore this further but patient retention may be difﬁcult for this study design.
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Dornase alpha is routinely inhaled by cystic ﬁbrosis patients to liquefy the tenacious
mucus in their lungs.
In an earlier study inhibition of the DNA hydrolyzing activity of dornase alpha
by azithromycin was reported at DNA levels below the levels found in CF
sputum (Ripoll, J Antimicrob Chemotherapy 1996). Azithromycin and dornase
alpha are used concomitantly in patients with cystic ﬁbrosis and are both found
in substantial concentrations in sputum. We investigated the possible interaction at
clinical representative sputum-levels of azithromycin, dornase alpha and DNA. To
study the dornase alpha activity we determined the effect of dornase alpha (with
or without azithromycin) on the kinematic viscosity of a DNA solution. Kinematic
viscosity was determined with a micro-viscosimeter.
These experiments showed that 50mg/l azithromycin did not, and 100mg/l
azithromycin did slightly affect the capacity of dornase alpha (present at 10, 0.2
and 0.04mg/l) to lower the viscosity of a solution containing 2.6 g/l DNA.
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Rationale: The primary cause of morbidity and mortality in CF is progressive lung
disease due to PA infection. New inhaled anti-PA antibiotics are needed to slow
lung disease progression.
Methods: This is an ongoing open label trial with patients who previously
participated in one of two double blind, placebo controlled trials. Patients receive
75mg AZLI (BID or TID) in up to nine 28 day on/off cycles over 18 months.
Change in FEV1 % predicted, respiratory symptoms (CFQ-R), sputum PA density
and safety endpoints are evaluated. Results for the ﬁrst 6 AZLI cycles (n = 120
patients) are presented.
Results: FEV1 % predicted improved compared to baseline after each cycle; at 12
months, mean relative change was 5.3% for the TID group. Respiratory symptoms
improved in the TID group after each cycle; at 12 months, mean scores increased
4.2 points. Sputum PA density was consistently below baseline; mean density was
reduced 0.4 log10 at 12 months. Across endpoints, TID outperformed BID dosing.
The safety proﬁle reﬂects the patients’ underlying CF lung disease and no notable
changes in cough, bronchospasm, hemoptysis or hospitalization rates were observed
with repeated exposure.
Conclusions: The therapeutic effect of TID AZLI therapy was robust and persistent
for six 28 day cycles (12 months). BID dosing was beneﬁcial, but TID results were
consistently better. Repeated exposure to AZLI is safe and effective in CF patients
with moderate to severe lung disease.
